WALTHAM, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company
focused on bioprocessing technology leadership, today announced that it will present at the 37th Annual J.P. Morgan
Healthcare conference being held January 7-10 at the Westin St. Francis in San Francisco. Tony J. Hunt, President and Chief
Executive Officer, will make a formal presentation on Tuesday, January 8, at 5:30 p.m. PST.
A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited
period of time following the conference event.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing-focused company that develops and commercializes highly innovative products
that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products
(Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography
resins, ELISA kits) and filtration products (XCell™ ATF systems, SIUS™ flat sheet TFF cassettes, and Spectrum KrosFlo™ hollow fiber
TFF cartridges and systems). The Protein A ligands and growth factor products that we produce are key components of Protein A
affinity resins and cell culture media, respectively. Protein A affinity resins are the industry standard for downstream separation
and purification of monoclonal antibody-based therapeutics. Growth factors are used in upstream processes to accelerate cell growth
and productivity. Our innovative line of OPUS® chromatography columns, used in downstream processes for bench-scale to
commercial-scale purification needs, are delivered pre-packed and customized to our customers choice of resin and packed bed
height. Our XCell™ ATF Systems, available in stainless steel and single-use configurations, continuously eliminate waste from a
bioreactor to concentrate cells and significantly increase productivity in upstream processes. Single-use SIUS™ TFF cassettes and
hardware are used for biologic drug concentration in downstream filtration processes. Spectrum KrosFlo™ TFF cartridges and systems
are used in both upstream and downstream filtration processes. Repligen’s corporate headquarters are in Waltham, MA (USA), with
additional administrative and manufacturing operations at locations including Shrewsbury, MA, Rancho Dominguez, CA, Lund, Sweden
and Ravensburg, Germany.
This press release may contain forward-looking statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which are not strictly historical statements including, without
limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to
time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any
forward-looking statements, except as required by law.
Source:
Repligen Corporation
Sondra Newman
Senior Director Investor Relations
(781) 419-1881
snewman@repligen.com
